Fundamental Analysis of X4 PHARMACEUTICALS INC(NASDAQ:XFOR) stock

Fundamental Rating

Overall XFOR gets a fundamental rating of 1 out of 10. We evaluated XFOR against 588 industry peers in the Biotechnology industry. XFOR may be in some trouble as it scores bad on both profitability and health. XFOR has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

XFOR had negative earnings in the past year.

In the past year XFOR has reported a negative cash flow from operations.

XFOR had negative earnings in each of the past 5 years.

In the past 5 years XFOR always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -68.70%, XFOR is not doing good in the industry: 64.33% of the companies in the same industry are doing better.

XFOR has a Return On Equity of -197.99%. This is in the lower half of the industry: XFOR underperforms 70.82% of its industry peers.

		Industry Rank	Sector Rank
ROA	-68.7%
ROE	-197.99%
ROIC	N/A

ROA(3y)-72.75%

ROA(5y)-60.4%

ROE(3y)-162.49%

ROE(5y)-122.83%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XFOR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, XFOR has more shares outstanding

Compared to 5 years ago, XFOR has more shares outstanding

XFOR has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -5.01, we must say that XFOR is in the distress zone and has some risk of bankruptcy.

XFOR has a worse Altman-Z score (-5.01) than 62.97% of its industry peers.

A Debt/Equity ratio of 1.07 is on the high side and indicates that XFOR has dependencies on debt financing.

XFOR has a Debt to Equity ratio of 1.07. This is in the lower half of the industry: XFOR underperforms 78.16% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.07
Debt/FCF	N/A
Altman-Z	-5.01

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

XFOR has a Current Ratio of 5.34. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 5.34, XFOR is in line with its industry, outperforming 57.00% of the companies in the same industry.

XFOR has a Quick Ratio of 5.34. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.

XFOR's Quick ratio of 5.34 is in line compared to the rest of the industry. XFOR outperforms 57.85% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.34
Quick Ratio	5.34

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

XFOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.91%, which is quite impressive.

EPS 1Y (TTM)67.91%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q65.52%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 16.34% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y22.77%

EPS Next 2Y11.02%

EPS Next 3Y16.9%

EPS Next 5Y16.34%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XFOR. In the last year negative earnings were reported.

Also next year XFOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

XFOR's earnings are expected to grow with 16.90% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y11.02%

EPS Next 3Y16.9%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for XFOR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (5/3/2024, 7:27:16 PM)

After market: 1.13 -0.02 (-1.74%)

1.15

+0.07 (+6.48%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap193.13M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-68.7%
ROE	-197.99%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	1.07
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	5.34
Quick Ratio	5.34
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)67.91%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y22.77%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

X4 PHARMACEUTICALS INC (XFOR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens